register

News - MedTech & Diagnostics

Westmead Private first in the state to implant neurosurgery medical device

Health Industry Hub | February 12, 2021 |

MedTech News: A medical device which is used to manage difficult-to-treat epilepsy is now available for the first time in a New South Wales private hospital.

Westmead Private Hospital has installed LivaNova’s most recent SenTiva Vagal Nerve Stimulator (VNS) in Australia, giving private patients access to treatment which was previously only available at one public hospital. 

The VNS is a device which is attached to a nerve in the neck and provides a current which may reduce the number of seizures a person experiences over time as well as improve the person’s overall quality of life. 

The device was implanted by Westmead Private Hospital neurosurgeon, Professor Mark Dexter, who is also Director of the Epilepsy Surgery Program at Westmead Health Precinct. 

Dr Michael Fong from Neurology New South Wales said giving patients access to neurostimulation at Westmead Private Hospital was a great milestone. 

“More than one-third of patients with epilepsy can’t control their condition with anti-seizure medications. For some of them, surgery may be an option but for many this is too risky or not possible for their epilepsy type,” Dr Fong said. 

You may also like Zimmer to spin off spine and dental business

“Neurostimulation can help reduce the abnormal electrical activity of the brain, which results in seizures, and the most established way of performing neurostimulation is a Vagal Nerve Stimulator.” 

“Not only has Westmead Private placed the first privately inserted VNS devices in New South Wales, it is also the first in Australia to utilise the most up-to-date technology in SenTiva.  This new device is only about the size of a 50 cent coin and is significantly smaller than previous models,” he said. 

Westmead Private Hospital’s SenTiva VNS also provides great benefit to regional patients looking to be fitted with the device, because they need fewer return visits to hospital for examination. 

Unlike previous models which required fortnightly to monthly check-ups with the patient, the SenTiva VNS allows the neurologist to determine up to three months therapy before they need to see the patient again. 

The SenTiva device also allows a different amount of therapy to be scheduled between night and day which can be invaluable in patients whose seizures occur predominantly at the same time.  


News - Pharmaceuticals

New vaccine guidelines risk further decline in vaccine uptake

New vaccine guidelines risk further decline in immunisation

Health Industry Hub | August 11, 2026 |

The intensifying political and public scrutiny of Dr Anthony Fauci has become emblematic of a wider struggle over trust in […]

More


News - Pharmaceuticals

The weight of the wait: GLP-1 boom hits PBS roadblock

The weight of the wait: GLP-1 boom hits PBS roadblock

Health Industry Hub | August 11, 2026 |

More than one million Australians have been dispensed a GLP-1 receptor agonist over the past five years, accelerating the emergence […]

More


News - MedTech & Diagnostics

As insurer blame game escalates, patients miss out on the promise of private health

As insurer blame game escalates, patients miss out on the promise of private health

Health Industry Hub | August 11, 2026 |

The Age and Sydney Morning Herald’s investigation into the Prescribed List (PL) and the pricing of medical devices has drawn […]

More


Leadership & Management

David Henderson appointed Takeda Oceania Country Head

David Henderson appointed Takeda Oceania Country Head

Health Industry Hub | August 10, 2026 |

David Henderson has been appointed Country Head for Takeda Oceania, succeeding Dave Pearce, as the pharmaceutical company continues to reshape […]

More


This content is copyright protected. Please subscribe to gain access.